Table 1. Demographics and clinical characteristics as predictive factors of the response to migraine prophylaxis using topiramate.
| Total (n=113) | Responders (n=70) | Nonresponders (n=43) | p | |
|---|---|---|---|---|
| Sex (male:female) | 43:70 | 29:41 | 13:30 | 0.232 |
| Age at diagnosis, years | 11.8±2.8 | 11.7±2.9 | 11.9±2.8 | 0.650 |
| Age at onset, years | 10.3±2.8 | 10.4±2.9 | 10.2±2.7 | 0.780 |
| Treatment duration, months | 8.3±5.1 | 8.5±5.8 | 7.9±3.8 | 0.492 |
| Disease duration, months | 17.3±15.8 | 15.5±14.0 | 20.3±18.2 | 0.120 |
| Headache duration, hours | 6.3±8.9 | 7.0±9.4 | 5.1±7.9 | 0.260 |
| Headache frequency per month | 14.9±9.6 | 15.3±9.7 | 14.2±9.5 | 0.575 |
| NRS score ≥6, % | 73 (64.6) | 48 (68.6) | 25 (58.1) | 0.260 |
| Impairment of daily activities, % | 74 (65.4) | 51 (72.9) | 23 (53.5) | 0.035 |
| Presence of family history, % | 54 (47.8) | 30 (42.9) | 24 (55.9) | 0.181 |
| Associated symptoms, % | ||||
| Nausea | 99 (87.6) | 60 (85.7) | 39 (90.7) | 0.435 |
| Vomiting | 31 (27.4) | 17 (24.3) | 14 (32.6) | 0.339 |
| Photophobia | 51 (45.1) | 32 (45.7) | 19 (44.2) | 0.874 |
| Phonophobia | 20 (17.7) | 12 (17.1) | 8 (18.6) | 0.799 |
| Dizziness | 60 (53.1) | 38 (54.3) | 22 (51.2) | 0.747 |
| Visual symptoms | 13 (11.5) | 7 (10.0) | 6 (14.0) | 0.523 |
Data are mean±standard deviation or n (%) values.
NRS: Numeric Rating Scale.